Respiratory infections are among the leading causes of illness and death in the elderly, driven by immune aging, chronic ...

CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development ...

The decision to end the programme comes 18 months after Genmab's former partner for the acasunlimab, BioNTech, pulled out of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. On the regional level, as the Human Development Index ...

Researchers at the Francis Crick Institute and AlveoliX have developed the first human 'lung-on-chip' model using stem cells ...

For the first time, a breathing lung model has been made using cells from only one person. Announced on January 1, the development comes from researchers at the Francis Crick Institute in London and ...

Pulmonary hypertension (PH) has a high mortality rate if untreated. Unfortunately, the disease is not consistently diagnosed or treated across the United States. To improve the diagnosis and care of ...

Dec 3 (Reuters) - Roivant (ROIV.O), opens new tab will discontinue the development of its drug for a rare lung disease after it failed to show treatment benefits in patients in a mid-stage trial.

Image of a lung lobe from a carcinogen-exposed mouse. Cells expressing the basal cell marker KRT5 have been fluorescently labelled and can be seen spreading throughout the bronchial tree The ‘cell of ...

A 60-year-old’s routine health screening revealed stage 1 lung cancer – a reminder that the disease can strike anyone, and ...